3.31
-0.10 (-2.93%)
| Previous Close | 3.41 |
| Open | 3.38 |
| Volume | 41,354 |
| Avg. Volume (3M) | 287,668 |
| Market Cap | 6,315,741 |
| Price / Earnings (TTM) | 0.008 |
| Price / Book | 0.430 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -5.09 |
| Total Debt/Equity (MRQ) | 4.15% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | -16.34 M |
| Levered Free Cash Flow (TTM) | -12.46 M |
| Return on Assets (TTM) | -59.80% |
| Return on Equity (TTM) | -204.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NuCana plc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Institutions | 0.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carlyle Group Inc. | 30 Sep 2025 | 133,333 |
| Glass Jacobson Investment Advisors Llc | 30 Sep 2025 | 15,000 |
| Allsquare Wealth Management Llc | 30 Jun 2025 | 1 |
| Cetera Investment Advisers | 30 Sep 2025 | 0 |
| Jump Financial, Llc | 30 Sep 2025 | 0 |
| Flagstone Financial Management | 30 Sep 2025 | 0 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |